05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£21,493,179 |
Nicolas Loebel |
3,538,991 |
£486,611 |
Junaid Bajwa |
1,193,697 |
£164,133 |
Jean Duvall |
1,163,529 |
£159,985 |
Jean Charest |
353,356 |
£48,586 |
Simon Sinclair |
256,327 |
£35,245 |
Carolyn Cross |
119,258,222 |
£16,398,006 |
M&G Plc |
67,254,901 |
£9,247,549 |
hInsight-NX, LLC |
42,272,654 |
£5,812,490 |
Robert Cross |
37,772,652 |
£5,193,740 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,077,059 |
CRUX Asset Management |
9,298,090 |
£1,278,487 |
Chelverton Asset Management |
7,957,311 |
£1,094,130 |
16:13 |
3,636 @ 13.75p |
14:05 |
20,000 @ 13.50p |
14:02 |
14,814 @ 13.51p |
14:00 |
14,814 @ 13.50p |
14:00 |
14,814 @ 13.50p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research